Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.
Type
Public
HQ
Malvern, US
Founded
2012
Size (employees)
18 (est)
Aclaris Therapeutics was founded in 2012 and is headquartered in Malvern, US

Aclaris Therapeutics Office Locations

Aclaris Therapeutics has an office in Malvern
Malvern, US (HQ)
400 101 Lindenwood Dr

Aclaris Therapeutics Data and Metrics

Aclaris Therapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(48.1 m)

EBIT (FY, 2016)

(48.6 m)

Market capitalization (26-May-2017)

663.3 m

Closing share price (26-May-2017)

25.2
Aclaris Therapeutics's current market capitalization is $663.3 m.
Numbers are in $, USDFY, 2015FY, 2016

R&D expense

15.3 m33.5 m

General and administrative expense

5.3 m15.1 m

Operating expense total

20.7 m48.6 m

EBIT

(20.7 m)(48.6 m)

Interest income

104 k

Net Income

(20.6 m)(48.1 m)
Numbers are in $, USDFY, 2015FY, 2016

Cash

9.9 m

Inventories

1.7 m

Current Assets

86.5 m

PP&E

360 k

Total Assets

94.1 m

Accounts Payable

810 k

Current Liabilities

1.6 m

Additional Paid-in Capital

135.5 m

Retained Earnings

(42.8 m)

Total Equity

92.5 m

Financial Leverage

1 x
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(20.6 m)(48.1 m)

Depreciation and Amortization

90 k120 k

Accounts Payable

(359 k)1.8 m

Cash From Operating Activities

(20.4 m)(34.6 m)

Purchases of PP&E

(507 k)(232 k)

Cash From Investing Activities

(77 m)(61.9 m)

Cash From Financing Activities

96.4 m116.8 m

Aclaris Therapeutics Market Value History

Aclaris Therapeutics News and Updates

Aclaris Therapeutics Company Life and Culture

You may also be interested in